NASH AMPK Exercise Dosing (AMPED) Trial

Description

There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD. While physical activity is recommended for all with NAFLD, how to best prescribe exercise as a specific treatment remains unknown, including what dose of exercise is most effective.

Conditions

NAFLD

Talk to us

Study Overview

On this page

Study Details

Study overview

There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD. While physical activity is recommended for all with NAFLD, how to best prescribe exercise as a specific treatment remains unknown, including what dose of exercise is most effective.

NASH AMPK Exercise Dosing (AMPED) Trial

NASH AMPK Exercise Dosing (AMPED) Trial

Condition
NAFLD
Intervention / Treatment

-

Contacts and Locations

Hershey

Penn State Hershey Medical Center, Hershey, Pennsylvania, United States, 17033

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18-69 years
  • * Sedentary \[\<90 min/wk of exercise identified by the Get Active Questionnaire (GAQ)
  • * BMI \>25kg/m2
  • * Liver biopsy within six months prior to enrollment showing:
  • * NASH defined by NASH Clinical Research Network (CRN) histology scoring system (NAS) \>4 and MRI-PDFF \>5% and;
  • * Liver fibrosis stage 1-3
  • * Active cardiac symptoms
  • * Body mass index (BMI) \>45kg/m2
  • * Cancer that is active
  • * Inability to walk \>2 blocks
  • * Institutionalized/prisoner
  • * Other liver disease
  • * Pregnancy
  • * Secondary hepatic steatosis
  • * Severe comorbidities
  • * AUDIT-C questionnaire identified significant alcohol use
  • * Substance abuse/active smoking
  • * Uncontrolled diabetes (changes in drug dosing over previous three months or A1c \>9%)
  • * GAQ response indicates exercise may be unsafe.

Ages Eligible for Study

18 Years to 69 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Milton S. Hershey Medical Center,

Jonathan G Stine, PRINCIPAL_INVESTIGATOR, Milton S. Hershey Medical Center

Study Record Dates

2026-06-01